In 2026, Vicarious Surgical, a U.S. surgical robot company that had once attracted significant capital investment due to its pioneering single-port plus VR manipulation technology, eventually declared bankruptcy and underwent liquidation after depleting its financial resources. The company's technology was considered overly ambitious and out of touch with industrial realities, posing hurdles for mass production. Furthermore, it repeatedly failed to secure FDA approval or progress to human clinical trial stages. During this same timeframe, China's MicroPort Robotics unveiled its first half-year profit forecast since its inception, marking a notable shift in the surgical robot industry's development paradigm. The emphasis has shifted from solely focusing on technical specifications to prioritizing the actual effectiveness of the equipment in real-world use, the rates of consumable repurchases, and the ability to generate self-sustaining cash flow.

The surgical robot industry is known for its lengthy commercialization journey, with numerous companies bowing out at various stages of development due to cash flow constraints. The primary reason for their downfall is their inability to navigate the entire commercialization process successfully. Presently, the global surgical robot market continues to expand, with domestic manufacturers intensifying their pursuit. Chinese manufacturers have clinched over 60% of the competitive bids for laparoscopic surgical robots and have made remarkable strides in overseas expansion, loss reduction, and strategic positioning in niche markets.

The industry's competitive landscape has shifted towards boosting equipment utilization rates and increasing the share of revenue derived from consumables to achieve positive cash flow. Industry behemoths like Mindray are also capitalizing on their channel strengths to penetrate this sector. To successfully traverse the extended industrialization cycle, cutting-edge technological advancements must closely align with clinical requirements and keep pace with mass production and commercialization efforts.